LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Generic: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Granules Pharmaceuticals Inc.Manufacturer
ORALRoute
LOSARTAN POTASSIUMActive Substance
2023-09-29Original Approval

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE is FDA application ANDA218015, sponsored by GRANULES. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class II2022-04-15
Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottles (NDC # 33342-045-07), b) 90-count bottles (NDC # 33342-045-1

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2019-02-28
Losartan Potassium Tablets USP, 50 mg, Rx only, a) 30 count (NDC 31722-701-30), b) 90 count (NDC 31722-701-90), c) 1000

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the act

Class II2022-04-15
Losartan Potassium Tablets, USP, 25 mg, a) 90-count bottles (NDC # 33342-044-10), b) 1000-count bottles (NDC # 33342-044

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2022-03-31
Losartan Potassium Tablets USP, 100 mg, a) 90-count bottles (NDC# 68180-378-03), b) 1000-count bottles (NDC# 68180-378

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2019-02-28
Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90 count (NDC 31722-702-30), c) 1000

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the act

Class II2019-02-28
Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31722-700-05) and c) 1

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the act

Class II2022-04-15
Losartan Potassium Tablets, USP, 100 mg, a) 30-count bottles (NDC # 33342-046-07), b) 90-count bottles (NDC # 33342-046-

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2022-06-06
Losartan Potassium Tablets, USP 50 mg, 90 Tablets bottles, Rx Only Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc.

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2022-06-06
Losartan Potassium Tablets, USP 100 mg, 90 Tablets bottles, Rx Only, Marketed and Packaged By: PD-Rx Pharmaceuticals, In

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class II2019-06-20
Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active p

Top Reported Reactions

1
FATIGUE
12,882 reports
2
DIARRHOEA
10,774 reports
3
NAUSEA
10,021 reports
4
DRUG INEFFECTIVE
10,013 reports
5
DYSPNOEA
9,113 reports
6
DIZZINESS
8,696 reports
7
HEADACHE
8,682 reports
8
PAIN
7,886 reports
9
OFF LABEL USE
7,841 reports
10
ARTHRALGIA
6,818 reports